If its label expansion is approved, earlier Pluvicto treatment may help patients avoid the toxic side effects of chemotherapy — and may open a larger market for the targeted treatment.
The conglomerate is focusing on building its cardiac health business and spent $16.6 billion to buy heart pump maker Abiomed in 2022 and $400 million to buy another heart-centric device maker Laminar.
The German drugmaker said it planned to reduce its customer-facing teams in favor of a hybrid in-person and virtual sales model by June 30, in large part because pharmacy benefit managers (PBMs) had kept branded Humira on their lists of medicines for reimbursement.
Yesterday the agency announced the approval of Zevtera for treating Staphylococcus aureus bloodstream infections, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia.
Sanofi has in principle reached a settlement related to its discontinued heartburn drug Zantac, though the French pharma did not disclose the financial terms of the deal.
A Delaware judge on Wednesday agreed with Roivant subsidiary Arbutus and Genevant’s interpretation of specific patent claims regarding the lipid nanoparticle delivery system used by Moderna’s COVID-19 vaccine.
The company will withdraw its amyotrophic lateral sclerosis (ALS) drug – its only product in the market – from the U.S. and Canada after the treatment failed in a key late-stage trial.
The approval marks a significant milestone for the American pharmaceutical company in the field of UC, following the approval by the FDA in October 2023 and the EMA approval in February 2024.
At the event, Biden and Sanders discussed issues including patent thickets, the cost of asthma inhalers and insulin, and proposals to expand the Medicare price negotiation provision of the 2022 Inflation Reduction Act.
The retailer will offer its members access to weight-loss programs, including prescription drugs Ozempic and Wegovy, from online healthcare services provider Sesame, as the companies expanded their partnership.
